Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China.

IF 4.7 2区医学 Q1 CLINICAL NEUROLOGY

Therapeutic Advances in Neurological Disorders Pub Date : 2024-04-13 eCollection Date: 2024-01-01 DOI:10.1177/17562864241239117

Jun Guo, Jiayong Wu, Lihua Wang, Hongbo Liu, Xiaomu Wu, Huan Yang, Wenyu Li, Honghao Wang, Bitao Bu, Chunsheng Yang, Hongyu Zhou, Shougang Guo, Yinan Zhao, Zhanhang Wang, Chunyang Li, De-Cai Tian, Sheng Chen, Huiru Xue, Yanlin Zhang, Yongfeng Xu, Hui Liang, Zhe Wu, Yu Zhang, Qiang Dong, Jiawei Wang, Chao Quan

{"title":"Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China.","authors":"Jun Guo, Jiayong Wu, Lihua Wang, Hongbo Liu, Xiaomu Wu, Huan Yang, Wenyu Li, Honghao Wang, Bitao Bu, Chunsheng Yang, Hongyu Zhou, Shougang Guo, Yinan Zhao, Zhanhang Wang, Chunyang Li, De-Cai Tian, Sheng Chen, Huiru Xue, Yanlin Zhang, Yongfeng Xu, Hui Liang, Zhe Wu, Yu Zhang, Qiang Dong, Jiawei Wang, Chao Quan","doi":"10.1177/17562864241239117","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country.</p>","PeriodicalId":22980,"journal":{"name":"Therapeutic Advances in Neurological Disorders","volume":"17 ","pages":"17562864241239117"},"PeriodicalIF":4.7000,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11015775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Neurological Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562864241239117","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the first oral DMT was approved in 2018, DMT approval accelerated, and seven DMTs were approved within 5 years. With an increasing number of DMTs being prescribed in clinical practice, it is necessary to discuss the standardized MS treatment algorithms depending on the disease activity and DMT availability. In this review paper, more than 20 Chinese experts in MS have reviewed the therapeutic progress of MS in China and worldwide and discussed algorithms for treating relapsing MS (RMS) based on the available DMTs in China, providing insights for establishing the standardized RMS treatment algorithms in this country.

查看原文本刊更多论文

复发性多发性硬化症的治疗算法：基于中国现有疾病改变疗法的探索。

多发性硬化症（MS）由于发病率低，在中国被定义为罕见病。长期以来，干扰素β是唯一获批的疾病修饰疗法（DMT）。自2018年首个口服DMT获批以来，DMT获批速度加快，5年内已有7种DMT获批。随着临床实践中处方的 DMT 越来越多，有必要讨论根据疾病活动性和 DMT 可用性的标准化 MS 治疗算法。在这篇综述论文中，20多位中国多发性硬化专家回顾了中国和世界范围内多发性硬化的治疗进展，并根据中国现有的DMTs探讨了治疗复发性多发性硬化（RMS）的算法，为中国建立标准化的RMS治疗算法提供了启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Neurological Disorders CLINICAL NEUROLOGY-

CiteScore

8.30

自引率

1.70%

发文量

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Neurological Disorders is a peer-reviewed, open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of neurology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in neurology, providing a forum in print and online for publishing the highest quality articles in this area.